Neuropathix Explained

Neuropathix Inc.
Type:Public
Founders:Dean Petkanas, Thoma Kikis
Location:Doylestown, Pennsylvania
Industry:Pharmaceutical Biotechnology
Assets:Patents,
Homepage:neuropathix.com

Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics.[1]

In 2016, through the company's subsidiary Kannalife, Neuropathix discovered KLS-13019[2] [3] [4] along with other therapeutic agents that prevent neuropathic pain, mitochondrial dysfunction, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Both KLS-13019 and cannabidiol, prevented the development of CIPN, while only KLS-13019 uniquely reversed neuropathic pain from chemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol.[5] Neuropathix family of monotherapeutic small molecules are focused on treating oxidative stress-related diseases, inflammation, chronic pain management and neurodegenerative disorders.

In late 2021, Neuropathix subsidiary Kannalife, was awarded a non-dilutive three-year $2.97 Million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and National Institutes of Health (NIH).[6] The three-year study grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for enhanced pain management and provides funding specifically in the Development of KLS-13019 for Neuropathic Pain.[7]

Neuropathix is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County to treat Chemotherapy-induced peripheral neuropathy, Hepatic encephalopathy, Mild Traumatic Brain Injury and CTE.[8]

Notes and References

  1. Web site: Cannabinoid series: a CBD-inspired molecule to increase bioavailability. Rees. Victoria. November 26, 2020. European Pharmaceutical Review. 2020-11-26.
  2. Kinney WA, McDonnell ME, Zhong HM, Liu C, Yang L, Ling W, Qian T, Chen Y, Cai Z, Petkanas D, Brenneman DE . 10 . Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability . ACS Medicinal Chemistry Letters . 7 . 4 . 424–8 . April 2016 . 27096053 . 4834656 . 10.1021/acsmedchemlett.6b00009 .
  3. Brenneman DE, Petkanas D, Kinney WA . Pharmacological Comparisons Between Cannabidiol and KLS-13019 . Journal of Molecular Neuroscience . 66 . 1 . 121–134 . September 2018 . 30109468 . 6150782 . 10.1007/s12031-018-1154-7 .
  4. Brenneman DE, Kinney WA, Ward SJ . Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity . Journal of Molecular Neuroscience . 68 . 4 . 603–619 . August 2019 . 31077084 . 6615992 . 10.1007/s12031-019-01321-z .
  5. Foss JD, Farkas DJ, Huynh LM, Kinney WA, Brenneman DE, Ward SJ . Behavioral and pharmacological effects of cannabidiol (CBD) and the CBD analogue KLS-13019 in mouse models of pain and reinforcement . British Journal of Pharmacology . April 2021 . 178 . 15 . 3067–3078 . 33822373 . 10.1111/bph.15486 . 233035597 . free .
  6. Web site: Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS). 2021-09-28. finance.yahoo.com. 28 September 2021 . en.
  7. Web site: Development of KLS-13019 for Neuropathic Pain. 2021-09-28. reporter.nih.gov. en.
  8. How cannabis is helping one company research treatment of CTE . Baskin. Ben. July 12, 2016. Sports Illustrated. 2016-07-12.